SEC filing record
Primary Source · SEC.gov

Citius Pharmaceuticals, Inc.

2021 vintageRule 506(b)Filing record

Built from the SEC filing index the day the filing landed. The figures below are the issuer's own from Form D; AltStreet's analysis, sponsor link and data flags follow when the entity is enriched.

Raised

$20M

Investors

7

Min Invest

None stated

AltStreet Verified Issuer badge

Is this your company or fund? Claim this page free, or verify it and carry the Verified Issuer mark.

What this filing shows

·

Every sentence is a value as filed on SEC Form D

Citius Pharmaceuticals, Inc. is a Nevada corporation that first filed a Form D on December 8, 2016 and most recently amended it on February 1, 2021 in the Pharmaceuticals industry group. The offering claims Rule 506(b) and covers equity. Citius Pharmaceuticals, Inc. reported $20,000,012 sold from 7 investors of a $20,000,012 total offering as of the Form D filed February 1, 2021. The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated. The Form D names H.C. Wainwright & Co., LLC (CRD 375) as the recipient of sales compensation soliciting in NV, NY. The issuer's address of record is 11 Commerce Drive, 1st Floor, Cranford, NJ 07016.

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0001506251
Entity NameCitius Pharmaceuticals, Inc.
ExemptionRule 506(b)
What the exemption meansRule 506(b) of Regulation D: securities may be sold to an unlimited number of accredited investors and up to 35 non-accredited investors who meet the rule's sophistication standard, without general solicitation or advertising.
Entity TypeCorporation
Jurisdiction of OrganizationNevada
Issuer Address11 Commerce Drive, 1st Floor, Cranford, NJ 07016
Phone(908) 967-6676
Former NamesTrail One, Inc. (until September 18, 2014); TrailOne, Inc. (until January 21, 2011)
Industry / Fund TypePharmaceuticals
Securities TypeEquity
First Sale DateJanuary 27, 2021
Filing DateFebruary 1, 2021
Accession Number0001213900-21-005652
Total Offering Amount$20,000,012
Total Amount Sold$20,000,012
Amount Remaining$0
Total Investors7
Non-Accredited InvestorsNone
Minimum Investment$0 (no stated minimum)
Offering DurationOne year or less
Revenue RangeDecline to Disclose
State (Issuer Address)NJ
Amendment Count7 filings on record

Filings on Record

Every filing AltStreet's ledger holds for this CIK, newest first. Each opens the SEC archive folder.

In the Terminal

Filing events

0

none on file

Critical / warning

0 / 0

0 watch · 0 info

Statements extracted

0

none on file

NAV prints

0

none on file

Offering chains

6

closed, lapsed

Open in the terminal Watch this issuerInvestor $149/mo unlocks the values; Pro $349/mo adds the universe.

Investor

  • 6 offering timelines: velocity, share raised, first-sale lag, stalled flags

Pro

  • This issuer against its cohort: rank by velocity and share raised among offerings filed the same quarter
  • The same events, statements and NAV moves across every issuer, screenable, with unlimited watches and CSV

Counts and dates above are the free record. The values, the series and the comparisons are the seat. Loading your view…

Related Persons (Form D)

Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.

Myron Holubiak

Executive Officer, Director · Cranford, NJ

Leonard Mazur

Executive Officer, Director · Cranford, NJ

Suren Dutia

Director · Cranford, NJ

Carol Webb

Director · Cranford, NJ

William Kane

Director · Cranford, NJ

Howard Safir

Director · Cranford, NJ

Eugene Holuka

Director · Cranford, NJ

Jaime Bartushak

Executive Officer · Cranford, NJ

Placement Agents and Sales Compensation (Form D)

Who the issuer reported paying to sell the securities (Form D Item 12), with the FINRA registration number the filer gave. Source: SEC.gov.

H.C. Wainwright & Co., LLCCRD 375 on BrokerCheck

NEW YORK, NY · Soliciting in NV, NY

Questions About Citius Pharmaceuticals, Inc.

Each answer is built from the values on the SEC filing and the AltStreet ledger, not from the issuer's marketing.

What is Citius Pharmaceuticals, Inc.?

Citius Pharmaceuticals, Inc. is a Nevada corporation that filed a Form D with the SEC on February 1, 2021 in the Pharmaceuticals industry group. The filing claims Rule 506(b) for an offering of equity.

Is Citius Pharmaceuticals, Inc. legit?

AltStreet does not rate legitimacy; it reports the public record. Citius Pharmaceuticals, Inc. filed a Form D with the SEC on February 1, 2021 claiming Rule 506(b). A Form D is a notice of an exempt offering, not a review or approval of it. The newest notice reports $20,000,012 sold to 7 investors. AltStreet's enforcement record (SEC, FINRA and state actions) shows no action naming the issuer as of today. Before investing, confirm the filing on EDGAR, check the seller's registration on FINRA BrokerCheck, and read the offering documents, which a Form D does not include.

Is Citius Pharmaceuticals, Inc. registered with or approved by the SEC?

No. A Form D is a notice that an issuer is selling securities under an exemption from registration, and the SEC does not review, approve, or pass on the merits of the offering. The filing shows that Citius Pharmaceuticals, Inc. claimed Rule 506(b) and disclosed the items the form requires, such as the amount sold, the minimum investment, related persons, and anyone paid to sell the securities. It does not verify the issuer's claims or its business.

How much has Citius Pharmaceuticals, Inc. raised?

Citius Pharmaceuticals, Inc. reported $20,000,012 sold from 7 investors of a $20,000,012 total offering as of the Form D filed February 1, 2021.

Who can invest in Citius Pharmaceuticals, Inc.?

The offering relies on Rule 506(b), which permits sales to accredited investors and to no more than 35 non-accredited investors who meet a sophistication standard, and prohibits general solicitation. The filing reports no non-accredited investors. The filing lists the minimum investment as $0, meaning no minimum was stated.

What is the minimum investment in Citius Pharmaceuticals, Inc.?

The Form D lists the minimum investment as $0, which means the issuer did not state a minimum on the form. The offering documents, not the Form D, set the actual subscription terms.

Who is selling Citius Pharmaceuticals, Inc. and how are they paid?

The Form D names H.C. Wainwright & Co., LLC (CRD 375) as the recipient of sales compensation soliciting in NV, NY.

Who is behind Citius Pharmaceuticals, Inc.?

The Form D lists 8 related persons: Myron Holubiak, executive officer, director; Leonard Mazur, executive officer, director; Suren Dutia, director; Carol Webb, director; William Kane, director; Howard Safir, director; Eugene Holuka, director; Jaime Bartushak, executive officer. Form D Item 3 requires executive officers, directors, and promoters of the issuer to be listed.

Where is Citius Pharmaceuticals, Inc. located?

The issuer's address on its SEC filings is 11 Commerce Drive, 1st Floor, Cranford, NJ 07016. Its phone number of record is (908) 967-6676. It is organized under the laws of Nevada.

How long is the Citius Pharmaceuticals, Inc. offering open?

The issuer indicated that the offering is not intended to last more than one year. An issuer must amend its Form D annually while a continuing offering stays open; 1 amendment is on record for this CIK.

What is Citius Pharmaceuticals, Inc.'s revenue?

The issuer declined to disclose its revenue range on the Form D, which the form permits.

AltStreet Verified Issuer badge

Is this your company or fund?

Free claim: add your contact details, website, team and a description to this page. The filed facts stay as filed.

Verified Issuer, $480 a year: AltStreet checks the identity of your company and the authority of the person claiming it against your filings, confirms your contact details on a stated date and again at each renewal, and marks the page so people researching you find a current, attributed profile beside the public filing record. It is not a review of any offering.

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.